Search results
Here’s Why Jim Cramer Says You Should Not Buy Bristol-Myers Squibb Co (NYSE:BMY)
Insider Monkey via Yahoo Finance· 3 days agoWe recently published the list of 11 stocks Jim Cramer is bearish on. Bristol-Myers Squibb Co...
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
Benzinga via AOL· 16 hours agoOn Thursday, the FDA approved Geron Corporation's (NASDAQ:GERN) Rytelo (imetelstat) for adult...
Analyst Report: Bristol-Myers Squibb Co.
Argus Research via Yahoo Finance· 2 days agoBristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene ...
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 5 days agoBristol Myers Squibb & Co BMY announced on Saturday (June 1) results from the Phase 3 KRYSTAL-12...
Bristol’s $250,000 pill slows lung cancer growth by 7 weeks
San Francisco Chronicle· 5 days agoA Bristol Myers Squibb Co. lung cancer treatment delayed tumor growth by less than seven weeks in a closely watched clinical trial, a disappointing result after the company paid nearly $5 billion ...
Geron surges after winning first US FDA approval for blood disorder drug
Reuters· 18 hours ago, opens new tab surged more than 30% on Friday, a day after the company gained its first approval...
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients -...
Benzinga· 4 days agoOpdivo plus Yervoy combo shows significant survival benefits and higher response rates vs....
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Benzinga via Yahoo Finance· 2 days agoThursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of...
Dividends Are a Benefit, But Only From Companies That Can Afford to Pay Them | Investing.com
Investing.com· 4 days agoFew financial topics have been the subject of more articles than dividend investing, and for good...
A Journey Through Subchapter S / A Review of The Not So Obvious & The Many Traps That Exist For The...
JD Supra· 2 days agoIn the S corporation arena, tax advisors generally do not focus much attention on unreasonable...